2024
Management of recurrent and persistent malignant ovarian germ cell tumors: a narrative review
Nasioudis D, Pashankar F. Management of recurrent and persistent malignant ovarian germ cell tumors: a narrative review. International Journal Of Gynecological Cancer 2024, 34: 1454-1460. PMID: 38991656, DOI: 10.1136/ijgc-2023-005052.Peer-Reviewed Original ResearchMalignant ovarian germ cell tumorsOvarian germ cell tumorsGerm cell tumorsCell tumorsHigh-dose chemotherapy protocolsPlatinum-resistant diseasePlatinum-sensitive diseaseSecondary cytoreductive surgeryPlatinum-based chemotherapyStandard dose chemotherapyCytoreductive surgeryDose chemotherapyTumor relapseOptimal resectionChemotherapy protocolsGenomic alterationsSpecialized centersTumorTherapeutic approachesSensitive diseasePatientsChemotherapyNarrative reviewOptimal timingDisease
2021
Re: ‘Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysis’
Lockley M, Stoneham S, Shamash J, Pashankar F, Frazier L. Re: ‘Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysis’. European Journal Of Cancer 2021, 152: 255-256. PMID: 34099362, DOI: 10.1016/j.ejca.2021.05.001.Peer-Reviewed Original Research
2020
Re: A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice
Pashankar F, Frazier AL. Re: A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice. European Journal Of Cancer 2020, 130: 265-266. PMID: 32178968, DOI: 10.1016/j.ejca.2020.01.022.Peer-Reviewed Original Research
2019
Sustained Remission After Maintenance Irinotecan in Patient With Multiply Relapsed Hepatoblastoma
Natarajan E, Auerbach C, Cheron R, Pashankar F. Sustained Remission After Maintenance Irinotecan in Patient With Multiply Relapsed Hepatoblastoma. Journal Of Pediatric Hematology/Oncology 2019, 42: e659-e661. PMID: 31259823, DOI: 10.1097/mph.0000000000001544.Peer-Reviewed Original ResearchConceptsRecurrent hepatoblastomaIfosfamide/carboplatin/etoposide chemotherapyLong-term disease-free survivalCarboplatin/etoposide chemotherapyDisease-free survivalLimited treatment optionsAdjuvant chemotherapySecond relapseEtoposide chemotherapyFirst relapseMultiple relapsesSurgical resectionPoor prognosisTreatment optionsMetastatic hepatoblastomaHepatoblastomaRelapseChemotherapyIrinotecanChildrenRemissionResectionPostresectionPatientsPrognosisGrowing Teratoma Syndrome After Chemotherapy For Ovarian Immature Teratoma
Imran H, Siddiqui AH, Wilson F, Pashankar F. Growing Teratoma Syndrome After Chemotherapy For Ovarian Immature Teratoma. Journal Of Pediatric Hematology/Oncology 2019, 42: e630-e633. PMID: 31205224, DOI: 10.1097/mph.0000000000001525.Peer-Reviewed Original ResearchConceptsOvarian immature teratomaRecurrent immature teratomaImmature teratomaTeratoma syndromePediatric patientsMainstay of treatmentPostoperative chemotherapyGynecologic oncologistsPediatric oncologistsAdult providersChemotherapyPatientsOncologistsSyndromeTeratomaAdultsTreatmentSurgeryRecurrenceManagementMainstayAlfa-feto protein (AFP) as a predictor of outcome for children with germ cell tumors: A report from the malignant germ cell international consortium.
O'Neill A, Xia C, Krailo M, Shaikh F, Pashankar F, Billmire D, Olson T, Amatruda J, Villaluna D, Malogolowkin M, Rodriguez-Galindo C, Frazier A. Alfa-feto protein (AFP) as a predictor of outcome for children with germ cell tumors: A report from the malignant germ cell international consortium. Journal Of Clinical Oncology 2019, 37: 10036-10036. DOI: 10.1200/jco.2019.37.15_suppl.10036.Peer-Reviewed Original ResearchEvent-free survivalGerm cell tumorsAFP declinePediatric patientsCell tumorsTumor marker declineStart of chemotherapyDays of chemotherapyStandard-risk diseaseYears of ageAdult patientsRisk diseasePoor prognosisSerum AFPMarker declineStratified analysisPatientsChemotherapyTumorsInitial daysDaysDeclinePrognosisDisease
2018
Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?
Shah R, Xia C, Krailo M, Amatruda JF, Arul SG, Billmire DF, Brady WE, Covens A, Gershenson DM, Hale JP, Hurteau J, Murray MJ, Nicholson JC, Olson TA, Pashankar F, Rodriguez-Galindo C, Shaikh F, Stark D, Frazier AL, Stoneham S. Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults? Gynecologic Oncology 2018, 150: 253-260. PMID: 29884437, DOI: 10.1016/j.ygyno.2018.05.025.Peer-Reviewed Original ResearchConceptsCisplatin-based chemotherapyClinical trial organizationsGerm cell tumorsFive-year event-free survivalMalignant ovarian germ cell tumorsOvarian germ cell tumorsAge groupsCarboplatin-based chemotherapyTreatment-related toxicityEvent-free survivalEligible patientsExcellent OSMetastatic diseaseOverall survivalClinical outcomesFrontline treatmentSurvival outcomesMean agePeak incidenceCell tumorsDysgerminomaChemotherapyPatientsTrials OrganizationCarboplatinP3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs).
Grimison P, Lawrence N, Stockler M, Martin A, Yip S, Wong N, Yeung A, Friedlander M, Mazhar D, Pashankar F, Quinn D, McDermott R, Walker R, Winstanley M, Hanning F, Weickhardt A, Stevanovic A, Davis I, Toner G. P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs). Journal Of Clinical Oncology 2018, 36: tps4596-tps4596. DOI: 10.1200/jco.2018.36.15_suppl.tps4596.Peer-Reviewed Original Research
2017
Immature Ovarian Teratoma
Faure-Conter C, Pashankar F. Immature Ovarian Teratoma. Journal Of Pediatric Hematology/Oncology 2017, 39: 487-489. PMID: 28859031, DOI: 10.1097/mph.0000000000000950.Peer-Reviewed Original ResearchConceptsOvarian immature teratomaImmature teratomaPure ovarian immature teratomaFIGO stage IARole of chemotherapyImmature ovarian teratomaGrade 1 tumorsStandard of careAdjuvant chemotherapyAdult oncologistsMalignant relapseStage IAPediatric seriesOvarian teratomaPediatric teamAdult womenChemotherapyTumorsTeratomaUrgent needRelapsePatientsSurgeryOncologistsPediatrics
2016
Reduced and compressed cisplatin-based chemotherapy in children and adolescents with intermediate-risk extracranial malignant germ cell tumors: A report from the Children’s Oncology Group.
Shaikh F, Cullen J, Olson T, Pashankar F, Malogolowkin M, Amatruda J, Villaluna D, Krailo M, Billmire D, Rescorla F, Egler R, Dicken B, Ross J, Schlatter M, Rodriguez-Galindo C, Frazier A. Reduced and compressed cisplatin-based chemotherapy in children and adolescents with intermediate-risk extracranial malignant germ cell tumors: A report from the Children’s Oncology Group. Journal Of Clinical Oncology 2016, 34: 10512-10512. DOI: 10.1200/jco.2016.34.15_suppl.10512.Peer-Reviewed Original ResearchTreatment of childhood nasopharyngeal carcinoma (cNPC) with neoadjuvant chemotherapy (NAC) and concomitant chemoradiotherapy (CCRT): Results of the Children’s Oncology Group ARAR0331 study.
Rodriguez-Galindo C, Krailo M, Krasin M, McCarville M, Hicks J, Pashankar F, Pappo A. Treatment of childhood nasopharyngeal carcinoma (cNPC) with neoadjuvant chemotherapy (NAC) and concomitant chemoradiotherapy (CCRT): Results of the Children’s Oncology Group ARAR0331 study. Journal Of Clinical Oncology 2016, 34: 10513-10513. DOI: 10.1200/jco.2016.34.15_suppl.10513.Peer-Reviewed Original ResearchTreatment of childhood adrenocortical carcinoma (ACC) with surgery plus retroperitoneal lymph node dissection (RPLND) and multiagent chemotherapy: Results of the Children’s Oncology Group ARAR0332 protocol.
Rodriguez-Galindo C, Pappo A, Krailo M, Pashankar F, Monteiro Caran E, Hicks J, McCarville M, Weldon C, Malkin D, Zambetti G, Filho A, LaQuaglia M, Mastellaro M, Ribeiro R. Treatment of childhood adrenocortical carcinoma (ACC) with surgery plus retroperitoneal lymph node dissection (RPLND) and multiagent chemotherapy: Results of the Children’s Oncology Group ARAR0332 protocol. Journal Of Clinical Oncology 2016, 34: 10515-10515. DOI: 10.1200/jco.2016.34.15_suppl.10515.Peer-Reviewed Original Research
2015
Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International Collaborative
Pashankar F, Hale JP, Dang H, Krailo M, Brady WE, Rodriguez-Galindo C, Nicholson JC, Murray MJ, Bilmire DF, Stoneham S, Arul GS, Olson TA, Stark D, Shaikh F, Amatruda JF, Covens A, Gershenson DM, Frazier AL. Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International Collaborative. Cancer 2015, 122: 230-237. PMID: 26485622, PMCID: PMC5134834, DOI: 10.1002/cncr.29732.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAnalysis of VarianceBiopsy, NeedleChemotherapy, AdjuvantChildCohort StudiesDisease-Free SurvivalFemaleHumansImmunohistochemistryMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingOvarian NeoplasmsRegistriesRisk AssessmentSurvival AnalysisTeratomaYoung AdultConceptsImmature teratomaAdult clinical trialsGrade 1 diseaseOvarian immature teratomaRole of chemotherapyPostoperative chemotherapyPediatric patientsAdult trialsPediatric trialsPooled analysisClinical trialsStage IAdult womenTrialsChemotherapyCollaborative data setPatientsSurgeryTeratomaDiseaseWomen
2011
Acute Constipation in Children Receiving Chemotherapy for Cancer
Pashankar FD, Season JH, McNamara J, Pashankar DS. Acute Constipation in Children Receiving Chemotherapy for Cancer. Journal Of Pediatric Hematology/Oncology 2011, 33: e300-e303. PMID: 21941132, DOI: 10.1097/mph.0b013e31821a0795.Peer-Reviewed Original ResearchConceptsDevelopment of constipationAcute constipationRisk factorsBowel movement patternDiagnosis of constipationSeverity of constipationUse of vincristineSignificant risk factorsAggressive managementGroup of childrenPediatric GastroenterologyConstipationChemotherapyNutrition criteriaMore weeksCancerParental perceptionsNorth American SocietySignificant problemAmerican SocietyChildrenVincristineOpiatesLifestyleCombined use
2009
T1155 Constipation in Children Receiving Chemotherapy for Cancer: Prevalence, Risk Factors and Severity of the Problem
Season H, Pashankar F, Beardsley D, McNamara J, Pashankar D. T1155 Constipation in Children Receiving Chemotherapy for Cancer: Prevalence, Risk Factors and Severity of the Problem. Gastroenterology 2009, 136: a-511. DOI: 10.1016/s0016-5085(09)62354-4.Peer-Reviewed Original Research
2001
Successful Chemotherapeutic Decompression of Primary Endodermal Sinus Tumor Presenting With Severe Spinal Cord Compression
Pashankar F, Steinbok P, Blair G, Pritchard S. Successful Chemotherapeutic Decompression of Primary Endodermal Sinus Tumor Presenting With Severe Spinal Cord Compression. Journal Of Pediatric Hematology/Oncology 2001, 23: 170-173. PMID: 11305721, DOI: 10.1097/00043426-200103000-00010.Peer-Reviewed Original ResearchConceptsEndodermal sinus tumorSpinal cord compressionCord compressionRadiation therapySevere spinal cord compressionEpidural cord compressionExcellent tumor responseComplete neurologic recoveryCisplatin-based chemotherapyNeurologic recoverySinus tumorComplete paraplegiaTumor PresentingTumor responseRapid resolutionLaminectomyChemotherapyTherapyChildren